Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
You may also be interested in...
GSK Vaccines: Injecting Visibility
A broad vaccines portfolio, a blockbuster asset swap with Novartis, and an R&D revamp including significant, long-term investment in technology platforms have cemented GlaxoSmithKline’s leadership in a perennially lucrative business that is core to its corporate ethos. Why hasn’t anyone seemed to notice?
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.